Last reviewed · How we verify

Prevention of Ventricular Fibrillation — Treatment Landscape & Competitive Intelligence

Prevention of Ventricular Fibrillation (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Prevention of Ventricular Fibrillation, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Bretylium Tosylate BRETYLIUM Pfizer bretylium Beta-1 adrenergic receptor 1986-01-01
Cordarone AMIODARONE Pfizer Antiarrhythmic sodium channels, potassium channels, calcium channels 1985-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer · 2 drugs in Prevention of Ventricular Fibrillation

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Prevention of Ventricular Fibrillation:

Cite this brief

Drug Landscape (2026). Prevention of Ventricular Fibrillation — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/prevention-of-ventricular-fibrillation. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing